Teva Biopharmaceuticals USA (TBU) is committed to the discovery and development of improved, next generation and novel biopharmaceuticals for the treatment of disease and serious medical conditions. Using proprietary albumin fusion technology, TBU can improve and expand the use of established and novel biopharmaceuticals by developing drug candidates with reduced dosing frequency and increased safety.
The TBU development team has a significant track record in translating early drug opportunities into clinically-proven drug candidates. TBU’s research and manufacturing facility based in Rockville, Md., is fully equipped and capable of supporting both GLP development and cGMP manufacture of biologics. TBU has capitalized on the depth of our pipeline and the breadth of our technology to develop drug candidates that will address a broad spectrum of unmet medical needs including chemotherapy supportive care, autoimmune disorders, metabolic disorders, cardiovascular disease, and enzyme replacement therapy.
Extended Duration Albumin Fusion Product Opportunities
Neugranin™
NeugraninTM is a protein derived from the direct genetic fusion of the genes for Granulocyte Colony Stimulating Factor (GCSF) and human serum albumin. This fusion produces a single polypeptide molecule that combines physiological properties of GCSF with the long half-life of serum albumin. NeugraninTM is currently under late-stage clinical development as an agent for the treatment of febrile neutropenia associated with chemotherapy.
Albuferon™ Beta
Albuferon-Beta is a product derived from the direct genetic fusion of the genes for human interferon-beta (IFN-beta) and human serum albumin. This fusion produces a single polypeptide molecule that combines the therapeutic activity of interferon-beta (IFN-beta) with the long half-life characteristics of human serum albumin and is under clinical investigation for treatment of multiple sclerosis (MS).
TBU's pipeline also includes multiple product candidates in earlier stages of development including both novel monoclonal antibody therapeutics and additional albumin fusion technology-based programs.
101502